Preimplantation Genetic Testing Market - Global Forecast 2026-2032 Market To Reach USD 1.97 Billion As NGS, AI-Enabled Labs, And Precision IVF Drive 12.36% CAGR


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI with accredited NGS workflows, faster turnaround, clear reporting, IVF software integration, AI-enabled lab efficiency, regional partnerships, and affordability models.

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Preimplantation Genetic Testing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The preimplantation genetic testing (PGT) market research report provides a comprehensive assessment of industry growth, technology adoption, clinical applications, regional dynamics, and strategic opportunities. The market is projected to reach USD 981.15 million in 2026 and expand at a CAGR of 12.36% to USD 1.97 billion by 2032. Its insights support strategic planning, competitive positioning, and market-entry decisions across fertility services, reproductive genetics, and laboratory technologies.

Market Overview and Growth Drivers

PGT is an increasingly important component of assisted reproductive technology, enabling fertility centers to assess embryos for chromosomal aneuploidy, monogenic disorders, and structural rearrangements before transfer. Key testing categories include:

  • PGT-A: Testing for chromosomal aneuploidy
  • PGT-M: Testing for monogenic disorders
  • PGT-SR: Testing for structural chromosomal rearrangements

Laboratory workflows are supported by next-generation sequencing (NGS), polymerase chain reaction, single-nucleotide polymorphism analysis, and whole-genome amplification. Demand is reinforced by infertility prevalence, delayed parenthood, inherited-disease awareness, and expanding access to genomic medicine. The World Health Organization estimates that approximately one in six adults experiences infertility during their lifetime.

Transformative Industry Shifts

Advances in NGS, embryo biopsy, vitrification, and integrated fertility-clinic data systems are improving testing capabilities. Trophectoderm biopsy at the blastocyst stage is widely used because it permits analysis of multiple cells while preserving the inner cell mass.

Clinical care is also shifting toward evidence-led, patient-specific planning supported by genetic counseling, laboratory accreditation, transparent reporting, and multidisciplinary review. However, mosaicism, reimbursement gaps, regulatory differences, ethical considerations, and test limitations continue to influence adoption. Understanding these constraints enables stakeholders to identify viable opportunities while mitigating clinical, regulatory, and reputational risks.

Artificial Intelligence and Digital Innovation

Artificial intelligence is emerging across embryo imaging analytics, laboratory quality control, workflow automation, and clinical decision support. Computer vision can improve consistency in embryo morphology assessment, while AI-enabled systems can monitor sample handling, flag workflow inconsistencies, and strengthen chain-of-custody controls.

Near-term value is expected to center on reducing variability, accelerating turnaround times, improving documentation, and supporting explainable decisions. Prospective validation remains essential before AI outputs can serve as standalone clinical determinants.

Regional Market Insights

  • North America: Benefits from extensive ART utilization, sequencing capacity, genetic counseling infrastructure, and laboratory accreditation, although insurance and policy differences affect access.
  • Europe: Features strong clinical governance and varied national rules governing embryo testing, storage, and permissible indications.
  • Asia-Pacific: Expands through investment in fertility services, genomic medicine, and private clinic networks, with affordability and regulation varying by country.
  • Latin America: Shows rising private-sector demand, particularly in Brazil and Mexico, despite affordability and regulatory challenges.
  • Middle East and Africa: GCC markets benefit from healthcare investment and genetic-disease awareness, while African access remains concentrated in urban private centers.

Strategic Market Group and Country Perspectives

The European Union and G7 combine advanced biomedical infrastructure with established regulatory oversight. BRICS markets offer significant growth potential through large patient populations and expanding fertility networks. ASEAN adoption is supported by medical tourism hubs, while GCC countries present opportunities for PGT-M and carrier-screening-linked IVF pathways.

The United States leads in commercial availability and laboratory scale. The United Kingdom, Germany, France, Italy, and Spain remain influential European markets, while China, India, Japan, South Korea, and Australia contribute substantial clinical and technology capacity. Country-level comparisons provide practical guidance for prioritizing partnerships, investments, and localized access strategies.

Strategic Priorities for Industry Leaders

  • Invest in accredited NGS workflows and validated mosaicism reporting protocols.
  • Strengthen genetic counseling and chain-of-custody controls.
  • Differentiate through turnaround time, reporting clarity, data security, and clinic-software integration.
  • Develop affordability models and clinician education programs for emerging markets.
  • Deploy AI initially in auditable, workflow-enhancing applications.
  • Communicate clearly that PGT does not guarantee pregnancy, live birth, or the absence of every genetic condition.

Key Takeaways from This Report

  • The market is forecast to nearly double from USD 981.15 million in 2026 to USD 1.97 billion by 2032.
  • NGS, AI, improved biopsy techniques, and digital laboratory systems are reshaping PGT delivery.
  • Regulation, affordability, counseling capacity, and laboratory quality remain central adoption factors.
  • Growth opportunities are strongest for providers combining clinical rigor, transparent communication, and region-specific strategies.

Key Attributes:

Report Attribute Details
No. of Pages 188
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $981.15 Million
Forecasted Market Value (USD) by 2032 $1970 Million
Compound Annual Growth Rate 12.3%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Preimplantation Genetic Testing Market, by Test Type
7.1. Introduction
7.2. PGT-A (Aneuploidy)
7.3. PGT-M (Monogenic Disorders)
7.4. PGT-SR (Structural Rearrangements)
7.5. PGT-HLA (Human Leukocyte Antigen Matching)
8. Preimplantation Genetic Testing Market, by Technology Type
8.1. Introduction
8.2. Comparative Genomic Hybridization
8.3. Fluorescent In-Situ Hybridization
8.4. Next-Generation Sequencing
8.5. PCR-Based Testing
8.6. Single-Nucleotide Polymorphism
9. Preimplantation Genetic Testing Market, by Offering
9.1. Introduction
9.2. Instruments
9.3. Reagents & Consumables
9.3.1. Kits
9.3.2. Probes
10. Preimplantation Genetic Testing Market, by Procedure Stage
10.1. Introduction
10.2. Embryo Biopsy
10.3. Polar Body Biopsy
10.4. Blastocyst Biopsy
11. Preimplantation Genetic Testing Market, by Application
11.1. Introduction
11.2. Aneuploidy Screening
11.3. Monogenic Diseases
11.4. IVF Prognosis
12. Preimplantation Genetic Testing Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Fertility Clinics
12.4. Hospitals
12.5. Research Institutes
13. Preimplantation Genetic Testing Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Africa
13.6. Latin America
13.7. Middle East
14. Preimplantation Genetic Testing Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. European Union
14.5. BRICS
14.6. ASEAN
14.7. GCC
15. Preimplantation Genetic Testing Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. Japan
15.6. India
15.7. United Kingdom
15.8. France
15.9. Australia
15.10. Canada
15.11. Italy
15.12. South Korea
15.13. Brazil
15.14. Russia
15.15. Mexico
15.16. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Agilent Technologies, Inc.
17.3. Bio-Techne Corporation
17.4. Bioarray S.L.
17.5. EUROPE IVF International s.r.o.
17.6. F. Hoffmann-La Roche AG
17.7. Genea Limited
17.8. GENETiKS
17.9. Illumina, Inc.
17.10. Invicta Genetics
17.11. Invitae Corporation
17.12. Juno Genetics, US Inc.
17.13. Laboratory Corporation of America Holdings
17.14. MedGenome Labs Ltd.
17.15. Merck KGaA
17.16. Natera, Inc.
17.17. NextGen Genetics Holdings, LLC
17.18. Ovation Fertility
17.19. PacGenomics
17.20. PerkinElmer, Inc.
17.21. Progyny, Inc.
17.22. Qiagen N.V.
17.23. Quest Diagnostics Incorporated
17.24. Reproductive Genetic Innovations, LLC
17.25. SEQUENCE46, LLC
17.26. Sysmex Corporation
17.27. Takara Bio Inc.
17.28. The Cooper Companies Inc.
17.29. Thermo Fisher Scientific Inc.
17.30. Vitrolife Sweden AB
17.31. Yikon Genomics (Shanghai) Co., Ltd.
18. Key Experts

List of Figures [23]
List of Tables [298]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112026004107003653ID1111990327


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search